Could a diabetes pill boost chemo response in breast cancer? new study investigates.
NCT ID NCT05989347
First seen May 27, 2026 · Last updated Jun 18, 2026 · Updated 5 times
Summary
This early-phase study looks at whether adding dapagliflozin, a diabetes drug, to standard chemotherapy changes insulin-related markers in the blood. It involves 20 women with early-stage HER2-negative breast cancer who also have high insulin levels. The goal is to gather safety data and understand how the drug affects insulin resistance, not to treat the cancer directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale Cancer Center Smilow Cancer Hospital
RECRUITINGNew Haven, Connecticut, 06520, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.